title: Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease.
authors.affiliation: Department I of Internal Medicine, Infectious Diseases, University of Cologne, Cologne, Germany. oliver.cornely@ctuc.de
authors.forename: Oliver A
authors.initials: OA
authors.lastname: Cornely
authors.forename: Johan
authors.initials: J
authors.lastname: Maertens
authors.forename: Mark
authors.initials: M
authors.lastname: Bresnik
authors.forename: Ramin
authors.initials: R
authors.lastname: Ebrahimi
authors.forename: Emma
authors.initials: E
authors.lastname: Dellow
authors.forename: Raoul
authors.initials: R
authors.lastname: Herbrecht
authors.forename: J Peter
authors.initials: JP
authors.lastname: Donnelly
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage*; D000935:Antifungal Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy* / Q000401:mortality; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B